论文部分内容阅读
本研究旨在探讨表没食子儿茶素没食子酸酯(EGCG)的降脂作用与Angptl3-LPL信号通路之间的关系。通过高脂饲料喂养建立高脂血症大鼠动物模型,将正常大鼠按体质量和体脂水平随机分为正常对照组、高脂模型组、EGCG高剂量组(EGCG-H,30 mg·kg~(-1)·d~(-1))、EGCG低剂量组(EGCG-L、15 mg·kg~(-1)·d~(-1))、T0901317组、EGCG-T0901317组(EGCG,30mg·kg~(-1)·d~(-1))。连续灌胃8周后,用生化法检测血清中TG、TC、LDL-C含量,qPCR法检测脂肪组织中脂蛋白脂肪酶(LPL)mRNA和肝组织中Angptl3 mRNA相对表达量,Western blot检测蛋白表达水平。给大鼠口服选择性的LXRs激动剂T0901317后测定肝脏Angptl3 mRNA和蛋白表达水平,评价EGCG对T0901317抑制剂的作用。结果表明,与高脂模型组相比,EGCG(30、15 mg·kg~(-1)·d~(-1))能有效降低大鼠的血脂水平,明显抑制肝脏Angptl3 mRNA和蛋白表达、上调脂肪组织LPL mRNA和蛋白表达水平(P<0.05或P<0.01),且EGCG(30mg·kg~(-1)·d~(-1))可有效抑制由T0901317引起的Angptl3 mRNA和蛋白的表达。本研究从一个新的角度揭示了EGCG通过抑制Angptl3-LPL信号通路来防治与高脂相关性疾病的可能机制,所以以Angptl3-LPL信号通路为调节靶标,可能成为治疗血脂紊乱的一条新途径。
This study aimed to investigate the relationship between the hypolipidemic effects of epigallocatechin gallate (EGCG) and the Angptl3-LPL signaling pathway. Animal models of hyperlipidemic rats were established by feeding with high-fat diet. The body weight and body fat of normal rats were randomly divided into normal control group, high-fat model group, high-dose EGCG group (EGCG-H, 30 mg · (-1), EGCG-L (15 mg · kg -1 · d -1), T0901317 group, EGCG-T0901317 group EGCG, 30 mg · kg -1 · d -1). Serum levels of TG, TC and LDL-C were detected by biochemical methods after 8 weeks of continuous gavage. The relative expression of lipoprotein lipase (LPL) mRNA and the expression of Angptl3 mRNA in adipose tissue were detected by qPCR. Western blot was used to detect the protein The expression level. Oral administration of T0901317, a selective LXR agonist, was performed to determine the expression of Angptl3 mRNA and protein in the liver and evaluate the effect of EGCG on T0901317 inhibitor. The results showed that compared with the model group, EGCG (30,15 mg · kg -1 · d -1) could effectively decrease the level of blood lipid and the expression of Angptl3 mRNA and protein in the liver, Upregulation of LPL mRNA and protein expression in adipose tissue (P <0.05 or P <0.01), and EGCG (30 mg · kg -1 · d -1) inhibited the expression of Angptl3 mRNA and protein induced by T0901317 expression. This study revealed a new perspective that EGCG can prevent and treat hyperlipemia-related diseases by inhibiting Angptl3-LPL signaling pathway. Therefore, targeting Angptl3-LPL signaling pathway may be a new way to treat dyslipidemia.